Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

WSU researcher develops potential vaccine for Chlamydia

A Wayne State University School of Medicine researcher has developed a potential first ever vaccine for Chlamydia, the world's most prevalent sexually transmitted disease and the leading cause of new cases of blindness.

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

Military personnel with TBI should receive adequate protein and calories immediately after trauma

To help alleviate the effects of severe traumatic brain injury (TBI), the U.S. Department of Defense should ensure that all military personnel with this type of injury receive adequate protein and calories immediately after the trauma and through the first two weeks of treatment, says a new report from the Institute of Medicine.

21 Apr 2011

Scientists discover 'small molecule' substance that blocks cholesterol formation in the brain

A needle-in-the-haystack search through nearly 390,000 chemical compounds had led scientists to a substance that can sneak through the protective barrier surrounding the brain with effects promising for new drugs for Parkinson's and Huntington's disease. They report on the substance, which blocks formation of cholesterol in the brain, in the journal, ACS Chemical Biology.

21 Apr 2011

Early musical study may provide cognitive benefits as we age

Those childhood music lessons could pay off decades later - even for those who no longer play an instrument - by keeping the mind sharper as people age, according to a preliminary study published by the American Psychological Association.

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date," said Dr. Ozkan Yalkinoglou, Medical Director of ABX-CRO.

20 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

In the first animal model of Amyotrophic Lateral Sclerosis (ALS), developed by Dr. Udai Pandey, Assistant Professor of Genetics at LSU Health Sciences Center New Orleans, Dr. Pandey's lab has found in fruit flies that blocking the abnormal movement of a protein made by a mutated gene called FUS also blocks the disease process.

20 Apr 2011

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.

20 Apr 2011

Swinburne University of Technology acquires Elekta's Neuromag TRIUX MEG system

Certain brain processes happen in the blink of an eye – and even faster – which has made pinpointing these events virtually impossible. The advent of magnetoencephalography (MEG) changed all that, enabling researchers to capture brain electrical activity measured in milliseconds, and offering the potential to reveal the nature of innumerable brain disorders and diseases.

From Elekta 20 Apr 2011

Scientists detect several biomarkers to screen active drugs for Batten disease

Goethe University and Harvard Medical School start screening for active ingredients for the treatment of Batten disease

20 Apr 2011

Panelists urge consumers to prepare for possible long-term care issues in the future

Panelists participating today on a Lincoln Financial Group-sponsored webcast focusing on long-term care issues urged consumers to adopt a "retirement mindset" and be certain to understand the funding options available well before a need arises.

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

Alzheimer’s diagnostic guidelines released

Neurologists and experts have come up with a set of guidelines to better diagnose Alzheimer's disease in the clinic for the first time in nearly three decades. The advice also helps doctors identify the earliest signs of the degenerative condition, even before symptoms of memory loss begin. The hope is that they can help patients prepare early, and eventually treat, the disease.

19 Apr 2011

New guidelines allow definition of pre-Alzheimer's

The emphasis on the need to diagnose Alzeheimer's during its earliest stages is also evident in Congress, where legislation introduced this month would create new, specific Medicare cost codes for early-disease diagnosis to address these steps, including the discussions between the physician and caregivers.

19 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

First Edition: April 19, 2011

Today's headlines include a report about new guidelines that will allow an earlier definition of Alzeheimer's and associated legislation that would make key, related changes in Medicare cost codes.

19 Apr 2011

Gene mutation in Tibetian Terrier dogs causes hereditary form of Parkinson's disease in humans

University of Missouri researchers believe both man and animal will benefit from their discovery that the same gene mutation found in Tibetan Terrier dogs can also be found in a fatal human neurological disorder related to Parkinson's disease.

19 Apr 2011

Spinal fluid analysis can help detect early stage Alzheimer's disease

A new study from the University of Gothenburg, Sweden, shows how analysing spinal fluid can help to detect Alzheimer's disease at an early stage. The researchers behind the study hope that their findings will contribute to a greater international breakthrough for this type of diagnostic method.

19 Apr 2011